EN | UA
EN | UA

Help Support

Back

Use of an antiviral mouthwash to reduce SARS-CoV-2 viral load in saliva

Use of an antiviral mouthwash to reduce SARS-CoV-2 viral load in saliva Use of an antiviral mouthwash to reduce SARS-CoV-2 viral load in saliva
Use of an antiviral mouthwash to reduce SARS-CoV-2 viral load in saliva Use of an antiviral mouthwash to reduce SARS-CoV-2 viral load in saliva

A randomized controlled study aimed to investigate whether a mouthwash with β-cyclodextrin–citrox mouthwash (CDCM) can minimize the viral load in the saliva.

See All

Key take away

The study favors the significance of using CDCM on day 1 (four hours following the initial dose) for minimizing coronavirus viral load in the saliva. For the long-term effect (seven days), CDMC seems to offer a little benefit than placebo in decreasing SARS-CoV-2 load in saliva.

Background

A randomized controlled study aimed to investigate whether a mouthwash with β-cyclodextrin–citrox mouthwash (CDCM) can minimize the viral load in the saliva.

Method

This multicentre, double-blind study enrolled RT-PCR-positive people (age 18-85 years) having asymptomatic to mild symptoms of coronavirus disease for <8 days. A total of 176 eligible adults were randomized to either the CDCM group or placebo group.

For seven days, 3 rinses daily were done. On the first day,  saliva sampling was carried out at 09.00 (T1), 13.00 (T2) and 18.00 (T3). On the following six days, 1 sample was taken at 15.00. For viral detection, quantitative RT-PCR was utilized.

Result

As per intention-to-treat assessment, CDCM showed superior efficacy over the course of 1 day when compared to placebo four hours following the initial dose, with a median percentage (log10copies/mL) reduction T1-T2 of -12.58%. In comparison with placebo (3.31 log10copies/mL), the low median value for the CDCM (3.08 log10copies/mL) was maintained by the 2nd  dose.

On the seventh day, a greater median percentage (log10copies/mL) decline in salivary SARS-CoV-2 load was reported in CDCM group vs. placebo group, as shown in Table 1:


These outcomes were verified by the per-protocol assessment.

Conclusion

In people having mild or asymptomatic coronavirus disease, CDCM (4 hours after the initial dose) exhibited a favorable effect in decreasing salivary viral load. For the long-term effect, the benefit to suggest CDMC seems to be limited, even if 3 daily rinses displayed a positive impact on decreasing the viral load in saliva seven days following the initial intake in people with high salivary SARS-CoV-2 load at the baseline. 

Source:

Clinical Microbiology and Infection

Article:

Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial

Authors:

Florence Carrouel et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru ua en
Try: